INFO SHEET
Immunogenicity Testing Evolved: EpiScreen® 2.0
This EpiScreen® 2.0 delivers all the required sensitivity, plus detailed data on specificity and mechanism of action, without the need for radioactive markers.t.
What’s Inside?
Discover how early immunogenicity detection can make a crucial difference in the success of your protein therapeutics. EpiScreen® 2.0, powered by flow cytometry, not only meets the sensitivity standards of traditional assays like [3H]-thymidine but also allows for an in-depth characterization of immune responses with multiplexed cell activation markers. Learn about our enhanced blood processing technique, optimized for high cell yield per donor, which elevates assay reliability and boosts confidence in your immunogenicity risk assessment.
Download the Case Study
Let's move medicine forward
The asset you’re developing right now can make a real difference for human health. Let us use our wealth of experience to deploy the best technologies, shorten lead times and implement effective risk mitigation strategies.
